Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS and Free State department of Agriculture take hands
2007-04-02

During the visit to the Faculty of Natural and Agricultural Sciences of the University of the Free State (UFS) were, from the left: Mr Casca Mokitlane (Member of the Executive Committee for Agriculture in the Free State), Prof. Herman van Schalkwyk (Dean of the Faculty of Natural and Agricultural Sciences at the UFS) and Mr Tshepiso Ramarakane (Head of the Department of Agriculture in the Free State).

Photo: Stephen Collett
 

There is a need for the University of the Free State (UFS) and the Free State Department of Agriculture to work together as partners to pursue the development of agriculture in the province.

Prof. Herman van Schalkwyk, Dean of the Faculty of Natural and Agricultural Sciences at the UFS and Mr Casca Mokitlane, Member of the Executive Council (MEC) in the Free State, recently held investigative discussions to determine how a more focused strategic leadership for the development of agriculture in the province can be established.

Mr Mokitlane visited the faculty on the Main Campus in Bloemfontein and exchanged information with Prof. Van Schalkwyk on development issues in agriculture. Certain important agricultural issues between the faculty and the department was identified in order to build a more vibrant and sustainable agricultural industry in the province.

A few issues that would contribute to the building of relationships for sectoral development such as agricultural research, the training of small farmers and the department’s guidance officers, the support of community projects and targets for the land reform process were also discussed.

Mr Mokitlane visited nine departments within the faculty, among others the Lengau Agricultural Training Centre, where he had short discussions with prospective black farmers.

According to Prof. Van Schalkwyk thorough training of black emerging farmers was discussed. It was clear to him that small farmers who have already completed their training are a priority for the faculty. Further discussions will continue at a later stage.

Mr Mokitlane was also informed about the research done at the faculty, training programmes offered and the roles the different divisions are playing in terms of community service. Postgraduate students informed the delegates of their specific research and studies.

“We have great appreciation for the time Mr Mokitlane and his colleagues from the Department of Agriculture spent listening to what the faculty can do for agriculture in the Free State and also the rest of the country,” said Prof. Van Schalkwyk.

“Both parties are in agreement that the one cannot function without the other. We must move closer to each other in the interest of agriculture to face the challenges ahead,” said Prof. Van Schalkwyk.

Media release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl@ufs.ac.za
30 March 2007

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept